The North America and Europe Pharmaceutical Stability & Storage Services Market was valued at USD 1.32 billion in 2024, and is projected to reach USD 1.92 billion by 2030, rising at a CAGR of 6.40%. Stringent regulatory requirements, increasing R&D investments, and globalization of clinical trials are some of the major factors driving market growth.
The rising demand for biosimilars is expected to drive market advancement. In recent years, the approval rate for biosimilars has significantly improved. As per the Amgen Biosimilars Trend Report published in 2020, the number of biosimilar approvals in the U.S. increased by 65% since the preceding year. As of 2023, 41 biosimilars were approved in the U.S., and over 70 were approved in the EU. The growing approval of biosimilars is likely to impact the market positively.
In addition, the shift toward personalized medicine in these regions necessitates stability testing tailored to the distinct features of individualized treatments, ensuring that patient-specific therapies remain effective. Technological innovations have also transformed the landscape, integrating automation, advanced data analytics, and real-time monitoring technologies, streamlining stability testing processes, and accelerating decision-making. These advancements enhance operational effectiveness and provide immediate insights into product behavior, further propelling market growth.
Furthermore, the pharmaceutical industries in North America and Europe benefit from highly developed infrastructure equipped with state-of-the-art facilities for stability testing and storage, supporting the complex requirements of modern pharmaceuticals, including temperature-sensitive products. The increasing pipeline of new drugs, especially biologics and specialty medicines with unique storage needs and shorter shelf lives, also drives demand for advanced stability and storage solutions.
The rising demand for biosimilars is expected to drive market advancement. In recent years, the approval rate for biosimilars has significantly improved. As per the Amgen Biosimilars Trend Report published in 2020, the number of biosimilar approvals in the U.S. increased by 65% since the preceding year. As of 2023, 41 biosimilars were approved in the U.S., and over 70 were approved in the EU. The growing approval of biosimilars is likely to impact the market positively.
In addition, the shift toward personalized medicine in these regions necessitates stability testing tailored to the distinct features of individualized treatments, ensuring that patient-specific therapies remain effective. Technological innovations have also transformed the landscape, integrating automation, advanced data analytics, and real-time monitoring technologies, streamlining stability testing processes, and accelerating decision-making. These advancements enhance operational effectiveness and provide immediate insights into product behavior, further propelling market growth.
Furthermore, the pharmaceutical industries in North America and Europe benefit from highly developed infrastructure equipped with state-of-the-art facilities for stability testing and storage, supporting the complex requirements of modern pharmaceuticals, including temperature-sensitive products. The increasing pipeline of new drugs, especially biologics and specialty medicines with unique storage needs and shorter shelf lives, also drives demand for advanced stability and storage solutions.
North America And Europe Pharmaceutical Stability & Storage Services Market Report Highlights
- The stability testing segment dominated the service segment. It held the largest revenue share of 73.8% in 2024. The rapid growth in the demand for biopharmaceuticals and personalized medicines is driving advancements in pharmaceutical stability services
- The storage segment is expected to grow at a CAGR of 5.8% over the forecast period, owing to the increasing focus on generics and biosimilars in developing regions.
- The small molecules segment dominated the market, with the largest revenue share of 79.4% in 2024. Recent advances in forecasting, structure-based design, imaging, automation, artificial intelligence, and machine learning have become critical facilitators for increasing small molecules lead optimization’s pace and success rates
- The large molecules segment is expected to grow at a significant CAGR from 2025 to 2030. This is due to the increasing adoption of large molecules such as proteins, nucleic acids, carbohydrates, living cells, and tissues.
- North America dominated the pharmaceutical stability & storage services market. It held the largest revenue share in 2024, driven by the growing pipeline of complex drugs, including biologics and personalized medicines, necessitating specialized stability testing and controlled storage solutions, fueling market expansion.
- Europe is also expected to account for a significant market share in the coming years. The UK has a strong emphasis on R&D in the pharmaceutical sector. As companies invest in developing new drugs and conducting clinical trials, there is an increased demand for stability testing and storage services to support these activities
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. North America and Europe Pharmaceutical Stability and Storage Services Market Variables, Trends, & Scope
Chapter 4. North America and Europe Pharmaceutical Stability and Storage Services Market: Service Business Analysis
Chapter 5. North America and Europe Pharmaceutical Stability and Storage Services Market: Molecule Business Analysis
Chapter 6. North America and Europe Pharmaceutical Stability and Storage Services Market: Country Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this North America and Europe Pharmaceutical Stability & Storage Services market report include:- Eurofins Scientific
- Intertek Group plc
- Lucideon Limited
- Element Materials Technology
- Q1 Scientific
- Reading Scientific Services Ltd.
- Catalent, Inc.
- Quotient Sciences
- Recipharm AB
- Almac Group
- Alcami Corporation
- BioLife Solutions, Inc.
- Sampled (Roylance Stability Storage Limited)
- Precision Stability Storage
- Broughton
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.32 Billion |
| Forecasted Market Value ( USD | $ 1.92 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Europe, North America |
| No. of Companies Mentioned | 15 |
